시장보고서
상품코드
1485069

중증 근무력증 치료 시장 - 세계 산업 규모, 동향, 기회, 예측, 치료 유형별, 최종 용도별, 지역별, 경쟁사별(2019-2029년)

Myasthenia Gravis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By End Use, Region and Competition, 2019-2029F

발행일: | 리서치사: TechSci Research | 페이지 정보: 영문 185 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

중증근무력증 치료제 세계 시장 규모는 2023년 19억 6,000만 달러에 달했으며, 예측 기간 동안 2029년까지 연평균 7.58%의 꾸준한 성장세를 보일 것으로 예상됩니다.

중증근무력증(MG)을 앓고 있는 사람들의 요구를 충족시키는 데 초점을 맞춘 광범위한 헬스케어 산업 중 가장 역동적이고 빠르게 발전하고 있는 분야입니다. 중증 근무력증은 근력 약화와 피로를 특징으로 하는 희귀한 자가면역성 신경근 질환으로 안구 근육, 안와 근육 및 전신 근육 그룹에 영향을 미치는 경우가 많으며, MG 치료 시장은 삶의 질을 개선하고 MG 증상을 관리하기 위한 다양한 치료 접근법, 의약품 및 지지 요법을 포괄합니다. 중증 근무력증 치료 시장은 주로 전 세계 MG 유병률 증가로 인해 크게 성장하고 있습니다.

시장 개요
예측 기간 2025-2029년
시장 규모 : 2023년 19억 6,000만 달러
시장 규모 : 2029년 30억 6,000만 달러
CAGR : 2024-2029년 7.58%
급성장 부문 병원 및 클리닉
최대 시장 북미

이 질환에 대한 인식이 높아짐에 따라 진단을 받고 치료를 원하는 환자 수가 증가하면서 효과적인 치료법에 대한 수요가 증가하고 있습니다. 의학 연구의 발전과 MG의 배경이 되는 면역학적 기전에 대한 이해도가 높아지면서 새로운 치료법이 개발되고 있습니다. 면역억제제, 아세틸콜린에스테라아제 억제제, 단클론항체는 MG 환자에게 사용할 수 있는 주요 의약품입니다. 이들 치료제는 면역 체계를 조절하고, 신경근육의 소통을 강화하며, 증상을 관리함으로써 효과를 발휘합니다. 이 시장에는 흉선 절제술 및 혈장 요법과 같은 지지 요법도 포함되며, 특정 경우에 권장될 수 있습니다. 시장에서는 연구개발에 대한 투자가 증가하고 있으며, 특정 면역 경로를 표적으로 하는 단일클론항체 요법이나 효능과 안전성을 개선한 신약의 가능성을 모색하고 있습니다. 맞춤형 표적 치료 접근법에 대한 수요 증가는 MG 치료의 미래를 좌우할 것으로 보입니다.

주요 시장 성장 촉진요인

중증 근무력증 유병률 상승

의학 연구의 발전

치료 접근방식의 진화

주요 시장 과제

제한적인 치료 옵션

높은 치료비

주요 시장 동향

임상시험 확대

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계의 중증근무력증 치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 치료 유형별(콜린에스테라제 억제제, 만성 면역 조절제, 단클론항체, 신속 면역치료, 흉선 적출술, 기타)
    • 최종 용도별(병원 및 진료소, 외래수술센터(ASC), 기타)
    • 지역별
    • 기업별(2023년)
  • 시장 맵
    • 치료 유형별
    • 최종 용도별
    • 지역별

제5장 아시아태평양의 중증근무력증 치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 치료 유형별
    • 최종 용도별
    • 국가별
  • 아시아태평양 : 국가별 분석
    • 중국
    • 인도
    • 호주
    • 일본
    • 한국

제6장 유럽의 중증근무력증 치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 치료 유형별
    • 최종 용도별
    • 국가별
  • 유럽 : 국가별 분석
    • 프랑스
    • 독일
    • 스페인
    • 이탈리아
    • 영국

제7장 북미의 중증근무력증 치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 치료 유형별
    • 최종 용도별
    • 국가별
  • 북미 : 국가별 분석
    • 미국
    • 멕시코
    • 캐나다

제8장 남미의 중증근무력증 치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 치료 유형별
    • 최종 용도별
    • 국가별
  • 남미 : 국가별 분석
    • 브라질
    • 아르헨티나
    • 콜롬비아

제9장 중동 및 아프리카의 중증근무력증 치료 시장 전망

  • 시장 규모와 예측
    • 금액별
  • 시장 점유율과 예측
    • 치료 유형별
    • 최종 용도별
    • 국가별
  • 중동 및 아프리카 : 국가별 분석
    • 남아프리카공화국
    • 사우디아라비아
    • 아랍에미리트(UAE)

제10장 시장 역학

  • 성장 촉진요인
  • 과제

제11장 시장 동향과 발전

  • 최근 동향
  • 제품 출시
  • 인수합병(M&A)

제12장 세계의 중증근무력증 치료 시장 : SWOT 분석

제13장 Porter의 Five Forces 분석

  • 업계내 경쟁
  • 신규 참여 가능성
  • 공급업체의 힘
  • 고객의 힘
  • 대체품의 위협

제14장 경쟁 구도

  • Alexion Pharmaceutical Inc.
  • Grifols International, S.A.
  • Avadel Pharmaceuticals, Plc.
  • Novartis AG
  • Pfizer, Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc.
  • Bausch Health Companies Inc.

제15장 전략적 제안

제16장 리서치사에 대해 & 면책사항

LSH 24.06.04

Global Myasthenia Gravis Treatment Market was valued at USD 1.96 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 7.58% through 2029. The Global Myasthenia Gravis Treatment Market is a dynamic and rapidly evolving sector within the broader healthcare industry, focused on addressing the needs of individuals suffering from Myasthenia Gravis (MG). MG is a rare autoimmune neuromuscular disorder characterized by muscle weakness and fatigue, often affecting the ocular, bulbar, and generalized muscle groups. The market for MG treatment encompasses a wide range of therapeutic approaches, pharmaceuticals, and supportive care options aimed at improving the quality of life and managing the symptoms of MG. The myasthenia gravis treatment market is witnessing significant growth primarily due to the increasing prevalence of MG worldwide.

Market Overview
Forecast Period2025-2029
Market Size 2023USD 1.96 Billion
Market Size 2029USD 3.06 Billion
CAGR 2024-20297.58%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

As awareness of this condition grows, more patients are being diagnosed and seeking treatment, driving the demand for effective therapies. Advancements in medical research and a better understanding of the underlying immunological mechanisms behind MG have led to the development of novel treatment options. Immunosuppressants, acetylcholinesterase inhibitors, and monoclonal antibodies are among the key pharmaceutical interventions available for MG patients. These treatments work by modulating the immune system, enhancing neuromuscular communication, and managing symptoms. The market also includes supportive therapies such as thymectomy and plasmapheresis, which may be recommended in certain cases. The market is witnessing increased investment in research and development, leading to the exploration of potential monoclonal antibody therapies targeting specific immune pathways and new drugs with improved efficacy and safety profiles. The rising demand for personalized and targeted treatment approaches is likely to shape the future of MG treatment.

Key Market Drivers

Rising Prevalence of Myasthenia Gravis

The rising prevalence of Myasthenia Gravis (MG) is a significant driver behind the robust growth of the global MG treatment market. MG is an autoimmune neuromuscular disorder that affects individuals of all ages, but its incidence appears to be increasing worldwide. This increase can be attributed to various factors, including improved diagnostic methods and greater awareness within the medical community and among the general population. In recent years, there has been a marked uptick in the number of MG diagnoses, with both developed and developing countries reporting a higher incidence of the disease. This rise in prevalence has created a growing pool of MG patients seeking medical attention and treatment. As more individuals are diagnosed, the demand for effective therapies to manage MG's debilitating symptoms has surged.

The increase in MG prevalence is not only confined to specific geographic regions but is a global phenomenon. This global nature of the rise in MG cases has drawn the attention of healthcare providers, pharmaceutical companies, and researchers worldwide, leading to a concerted effort to develop and improve treatment options. This trend is driven in part by an aging population, as MG is more commonly diagnosed in individuals over 40 years old, and the world's demographic landscape is shifting toward an older population. Additionally, growing environmental factors and changes in lifestyle may be contributing to the increased incidence of autoimmune disorders like MG. Pharmaceutical companies are investing in research and development to create more effective and targeted therapies, while healthcare providers are continually improving their diagnostic capabilities and patient care strategies. Moreover, the growth of patient advocacy groups and awareness initiatives is driving the MG treatment market forward by pushing for better access to care and treatment options for MG patients.

Advancements in Medical Research

Advancements in medical research have played a pivotal role in boosting the global Myasthenia Gravis (MG) treatment market. Myasthenia Gravis is a complex autoimmune neuromuscular disorder characterized by muscle weakness and fatigue. One of the key ways medical research has advanced the MG treatment market is by shedding light on the intricate interplay between the immune system and neuromuscular function. Scientists have uncovered critical pathways and cellular interactions that contribute to the development and progression of MG. This knowledge has enabled the development of novel therapeutic approaches that directly target these specific mechanisms, thereby offering more precise and effective treatment options.

Monoclonal antibodies, in particular, have emerged as a promising avenue for MG treatment. These antibodies can be designed to target specific immune components, such as antibodies or complement proteins, that play a significant role in the pathophysiology of MG. Drugs like eculizumab and rituximab have demonstrated their efficacy in managing MG symptoms, providing patients with more reliable and better-tolerated treatment options. The advancements in molecular biology and genetic research have allowed for a more in-depth exploration of the genetic factors contributing to MG susceptibility and disease severity. Personalized medicine, which tailors treatment plans to an individual's unique genetic profile and disease characteristics, is becoming a reality for MG patients. This approach can optimize therapy selection and dosing, improving treatment outcomes and reducing adverse effects.

The collaborative efforts of researchers, pharmaceutical companies, and healthcare institutions in conducting clinical trials have been instrumental in bringing new MG treatments to market. These trials serve as the foundation for regulatory approvals, allowing promising therapies to reach patients. The global MG treatment market is benefiting from an expanding pipeline of innovative drugs and interventions, which is further fueling its growth.

Evolving Treatment Approaches

The global Myasthenia Gravis (MG) treatment market is experiencing a significant boost driven by the evolving treatment approaches that are redefining how this autoimmune neuromuscular disorder is managed. Traditionally, the treatment of MG has relied on acetylcholinesterase inhibitors and immunosuppressants, but recent advances in medical research have led to the development of novel and more targeted therapeutic options, ushering in a new era for MG patients. One of the most transformative developments in the MG treatment market is the introduction of monoclonal antibodies. These biologic drugs are designed to specifically target the immune components responsible for MG, such as autoantibodies and complement proteins. Drugs like eculizumab and rituximab have shown impressive efficacy in controlling MG symptoms, often with fewer side effects compared to conventional treatments. Monoclonal antibodies are changing the treatment landscape by providing a more tailored and precise approach, which has been well-received by both patients and healthcare providers.

Immunomodulators, such as the complement inhibitor eculizumab, are emerging as a promising class of drugs for MG treatment. By intervening in the complement system's hyperactivity, these drugs can mitigate the autoimmune response responsible for MG, offering patients a way to manage their condition more effectively. Such novel approaches are not only improving patient outcomes but also expanding the treatment options available in the market. The advances in regenerative medicine and gene therapy are opening up new possibilities for MG treatment. Researchers are exploring the potential of stem cell therapies and gene editing techniques to modify or replace faulty genes that contribute to MG. While these approaches are still in the experimental phase, they hold significant promise for the future of MG treatment.

Key Market Challenges

Limited Therapeutic Options

The global Myasthenia Gravis (MG) treatment market has made significant strides in recent years, offering innovative approaches and medications to manage this complex autoimmune neuromuscular disorder. However, one of the primary challenges hampering the market's advancement is the limited number of therapeutic options available for MG patients. Some MG patients do not respond well to the available treatments, which can result in prolonged suffering and a lower quality of life. The absence of alternative therapies exacerbates the frustration for patients who do not experience symptom relief or experience intolerable side effects from existing medications. The side effects of current MG treatments, such as immunosuppressants, can be substantial and may include an increased risk of infections, weight gain, and other health issues. MG patients sometimes need to make difficult choices between managing the disease and managing the side effects, as there are limited alternatives available.

Despite the availability of treatments, many MG patients struggle to achieve adequate control of their symptoms, particularly during periods of exacerbation. This can lead to fluctuations in their ability to carry out daily activities and participate in social and professional life. The limited therapeutic options highlight unmet medical needs in the MG treatment market. Patients and healthcare providers are in search of more diverse and effective treatment alternatives that can address the unique requirements of individual MG cases.

High Treatment Costs

While significant progress has been made in the field of Myasthenia Gravis (MG) treatment, one formidable obstacle continues to hinder the global MG treatment market - the high cost of treatment. MG is a complex autoimmune neuromuscular disorder that affects individuals of all ages, and the expense associated with managing the condition poses a significant barrier to accessing effective care. Monoclonal antibodies, such as eculizumab and rituximab, have demonstrated remarkable efficacy in managing MG symptoms but are costly to manufacture and administer. The cost of these medications can place a considerable financial burden on both patients and healthcare systems.

MG is a chronic condition that often necessitates long-term treatment and regular monitoring. The recurring costs of medications, physician visits, diagnostic tests, and supportive care can accumulate over time, making MG a financially challenging condition for patients to manage. MG patients often require specialized care from neurologists, immunologists, and other healthcare professionals with expertise in neuromuscular disorders. Accessing specialized care can be expensive, especially for individuals without comprehensive health insurance coverage or in regions where specialized care centers are limited. MG can lead to indirect costs for patients, including lost income due to work disability, transportation expenses for frequent medical appointments, and the need for support services or in-home care, all of which contribute to the financial strain associated with MG..

Key Market Trends

Expanding Clinical Trials

The global Myasthenia Gravis (MG) treatment market is experiencing a notable boost due to the expanding landscape of clinical trials focused on developing innovative treatments for this complex autoimmune neuromuscular disorder. Clinical trials play a pivotal role in assessing the safety and efficacy of potential therapies, and the growing number of trials in the MG field is contributing to a broader and more diverse range of treatment options.

One of the key trends driving the expansion of clinical trials in MG is the increasing recognition of the unmet medical needs of MG patients. Traditional treatments have limitations, and many patients do not respond adequately or experience adverse effects, necessitating the exploration of novel therapies. This realization has spurred pharmaceutical companies, academic institutions, and research organizations to invest in MG research and develop experimental treatments. The proliferation of clinical trials is diversifying the MG treatment landscape by exploring a range of therapeutic approaches. Some trials are dedicated to investigating the effectiveness of monoclonal antibodies, while others explore immunomodulators, regenerative medicine, and gene therapy. This multifaceted approach is providing hope for MG patients who may have previously had limited treatment choices.

The expansion of clinical trials accelerates the pace of innovation in MG treatment. As more potential therapies progress through rigorous testing and reach the clinical trial phase, patients have access to cutting-edge treatments. Successful trials can lead to regulatory approvals, making new therapies available to a broader patient population. Another significant advantage of expanding clinical trials is the accumulation of valuable data. Clinical trial findings contribute to a deeper understanding of MG's pathophysiology and patient responses to different treatments. This wealth of information aids healthcare providers in making more informed treatment decisions and refining their approaches to MG management.

Segmental Insights

Treatment Type Insights

Based on Treatment Type, the monoclonal antibodies emerged as the dominating segment in the Global Myasthenia Gravis Treatment Market in 2023. Monoclonal antibodies provide precise therapy by selectively binding to specific proteins implicated in the development of myasthenia gravis. This focused approach minimizes unintended effects and improves treatment effectiveness. In contrast to conventional treatments like corticosteroids and immunosuppressants, monoclonal antibodies frequently result in fewer overall side effects. This characteristic enhances their appeal to both patients and healthcare providers seeking treatments with manageable side effect profiles. Progress in biotechnology has facilitated the creation of monoclonal antibodies with refined specificity, potency, and safety characteristics. These technological advancements have propelled monoclonal antibodies to the forefront of the myasthenia gravis treatment landscape. Patients often favor monoclonal antibodies due to their targeted mode of action, reduced side effects, and convenient administration methods such as intravenous infusion or subcutaneous injection.

End Use Insights

Based on End Use, Hospitals & Clinics emerged as the fastest growing segment in the Global Myasthenia Gravis Treatment Market in 2023. Myasthenia Gravis is a complex neuromuscular disorder that often requires multidisciplinary care. Patients may experience a range of symptoms, and their treatment needs can vary. Hospitals and clinics are equipped with the specialized facilities, medical professionals, and diagnostic tools necessary to comprehensively manage MG. Treating MG patients often requires expertise in neurology, immunology, and other specialized fields. Hospitals and clinics typically have neurologists, immunologists, and neuromuscular specialists on staff or readily accessible through referrals, making them the go-to institutions for MG care. Accurate diagnosis of MG is crucial for effective treatment. Hospitals and clinics are well-equipped with the necessary diagnostic equipment, such as electromyography (EMG) and blood tests, to identify MG cases promptly and accurately.

Regional Insights

Based on region, North America emerged as the dominant region in the Global Myasthenia Gravis Treatment Market in 2023, holding the largest market share. North America, particularly the United States, has a relatively high prevalence of Myasthenia Gravis compared to other regions. This higher prevalence of MG patients has led to a greater demand for MG treatments, driving market growth. Research and Development Initiatives: North America is a hub for pharmaceutical research and development. The region is home to numerous pharmaceutical and biotech companies that actively invest in developing and testing MG treatments. Collaborations between these companies, academic institutions, and healthcare organizations lead to the creation of innovative therapies.

Key Market Players

Alexion Pharmaceutical Inc.

Grifols International, S.A.

Avadel Pharmaceuticals, Plc.

Novartis AG

Pfizer, Inc.

AbbVie Inc.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline plc.

Bausch Health Companies Inc.

Report Scope:

In this report, the Global Myasthenia Gravis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Myasthenia Gravis Treatment Market, By Treatment Type:

    Cholinesterase Inhibitors Chronic Immunomodulators Monoclonal Antibodies Rapid Immunotherapies Thymectomy Others

Myasthenia Gravis Treatment Market, By End use:

    Hospitals & Clinics Ambulatory Surgical Centers Others

Myasthenia Gravis Treatment Market, By Region:

    North America
    • United States
    • Canada
    • Mexico
    Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
    Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    South America
    • Brazil
    • Argentina
    • Colombia
    Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Myasthenia Gravis Treatment Market.

Available Customizations:

Global Myasthenia Gravis Treatment Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Myasthenia Gravis Treatment Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Treatment Type (Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy, Others)
    • 4.2.2. By End Use (Hospitals & Clinics, Ambulatory Surgical Centers, Others)
    • 4.2.3. By Region
    • 4.2.4. By Company (2023)
  • 4.3. Market Map
    • 4.3.1. By Treatment Type
    • 4.3.2. By End Use
    • 4.3.3. By Region

5. Asia Pacific Myasthenia Gravis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type
    • 5.2.2. By End Use
    • 5.2.3. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Myasthenia Gravis Treatment Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Treatment Type
        • 5.3.1.2.2. By End Use
    • 5.3.2. India Myasthenia Gravis Treatment Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Treatment Type
        • 5.3.2.2.2. By End Use
    • 5.3.3. Australia Myasthenia Gravis Treatment Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Treatment Type
        • 5.3.3.2.2. By End Use
    • 5.3.4. Japan Myasthenia Gravis Treatment Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Treatment Type
        • 5.3.4.2.2. By End Use
    • 5.3.5. South Korea Myasthenia Gravis Treatment Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Treatment Type
        • 5.3.5.2.2. By End Use

6. Europe Myasthenia Gravis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Myasthenia Gravis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By End Use
    • 6.3.2. Germany Myasthenia Gravis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By End Use
    • 6.3.3. Spain Myasthenia Gravis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By End Use
    • 6.3.4. Italy Myasthenia Gravis Treatment Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Treatment Type
        • 6.3.4.2.2. By End Use
    • 6.3.5. United Kingdom Myasthenia Gravis Treatment Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Treatment Type
        • 6.3.5.2.2. By End Use

7. North America Myasthenia Gravis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Myasthenia Gravis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By End Use
    • 7.3.2. Mexico Myasthenia Gravis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By End Use
    • 7.3.3. Canada Myasthenia Gravis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By End Use

8. South America Myasthenia Gravis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Myasthenia Gravis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By End Use
    • 8.3.2. Argentina Myasthenia Gravis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By End Use
    • 8.3.3. Colombia Myasthenia Gravis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By End Use

9. Middle East and Africa Myasthenia Gravis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Myasthenia Gravis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By End Use
    • 9.3.2. Saudi Arabia Myasthenia Gravis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By End Use
    • 9.3.3. UAE Myasthenia Gravis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By End Use

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Myasthenia Gravis Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. Alexion Pharmaceutical Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (In case of listed)
    • 14.1.5. Recent Developments
    • 14.1.6. SWOT Analysis
  • 14.2. Grifols International, S.A.
  • 14.3. Avadel Pharmaceuticals, Plc.
  • 14.4. Novartis AG
  • 14.5. Pfizer, Inc.
  • 14.6. AbbVie Inc.
  • 14.7. F. Hoffmann-La Roche Ltd.
  • 14.8. GlaxoSmithKline plc.
  • 14.9. Bausch Health Companies Inc.

15. Strategic Recommendations

16. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제